OncoMatch

OncoMatch/Clinical Trials/NCT05343013

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Is NCT05343013 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies TAS-102 for colorectal cancer.

Phase 2RecruitingM.D. Anderson Cancer CenterNCT05343013Data as of Jun 2026

Treatment: TAS-102To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

TAS-102

Cancer type

Colorectal Cancer

Disease stage

Required: Stage II, III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: platinum-based chemotherapy (oxaliplatin) — adjuvant

has completed all planned curative intent therapies that must include  3 months of oxaliplatin containing chemotherapy

Lab requirements

Blood counts

absolute neutrophil count: 1,000/mcL; platelets: 100,000/mcL

Kidney function

Serum creatinine  1.5 00 ULN or creatinine clearance 60 mL/min

Liver function

total bilirubin:  institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT): 3 0 institutional ULN

Has adequate organ and marrow function as defined below: 1. absolute neutrophil count: 1,000/mcL 2. platelets: 100,000/mcL 3. total bilirubin:  institutional upper limit of normal (ULN) 4. AST(SGOT)/ALT(SGPT): 3 00 institutional ULN 5. Serum creatinine  1.5 00 ULN or creatinine clearance 60 mL/min.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05343013 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received platinum-based chemotherapy.

What disease stage is eligible?

Stage II or III or IV is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify